Paper Details

  1. Home
  2. Paper Details

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.

Author: BlazarBruce R, CutlerCorey, DeFilippZachariah, KimHaesook T, LeeStephanie J, NoonanJohn, PavleticSteven Z, YangZhongming

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study identified 59 subjects with bronchiolitis obliterans syndrome (BOS) who were enrolled and treated in 2 prospective clinical trials of belumosudil, a novel oral selective rho-associated coiled-coil-containing protein kinase-2 inhibitor. The study found that belumosudil treatment was associated with lung-specific clinical responses for subjects with BOS, which were more commonly observed in less advanced disease.
Paper Details　
Original Abstract of the Article :
Chronic graft-versus-host disease (cGVHD) of the lung, or bronchiolitis obliterans syndrome (BOS), is a high-risk disease manifestation associated with poor outcomes. Currently available treatments have demonstrated limited clinical efficacy in this setting. Belumosudil is a novel oral selective rho...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792394/

データ提供：米国国立医学図書館（NLM）

Belumosudil: A New Hope for Bronchiolitis Obliterans Syndrome (BOS)?

The world of [chronic graft-versus-host disease (cGVHD)] treatment is in dire need of effective options. This study explores the potential of a new drug, [belumosudil], for treating [BOS], a serious complication of cGVHD that affects the lungs.

The study analyzed data from two clinical trials, examining the response of patients with [BOS] to treatment with [belumosudil]. Researchers focused on determining the [best overall response rate (ORR)] and identifying factors associated with a positive response.

The study showed a significant [ORR] of 32% among patients treated with [belumosudil]. The response rate was inversely proportional to the severity of [BOS] at the start of treatment, suggesting that [belumosudil] might be more effective in less advanced cases. Other factors associated with a positive response included [male sex], [lower baseline NIH cGVHD lung score], and [partial response to previous cGVHD therapies].

A New Treatment Option for a Challenging Condition

This study provides evidence that [belumosudil] can be effective in treating [BOS], particularly in less severe cases. This offers a glimmer of hope for patients facing this challenging condition.

Navigating the World of BOS: What Patients Need to Know

For patients with [BOS], understanding their condition and working closely with their doctor is crucial. This study emphasizes the importance of [early intervention], as [belumosudil] might be more effective in less advanced stages of the disease. If you are diagnosed with [BOS], it's essential to discuss all available treatment options with your doctor and to be vigilant in monitoring your condition.

Dr.Camel's Conclusion

This study sheds light on the potential of [belumosudil] as a promising treatment option for [BOS]. While more research is needed to fully understand its efficacy and to develop optimal treatment strategies, this study offers hope for patients with this debilitating condition. It is a testament to the ongoing efforts to find new and effective treatments for [cGVHD] and its complications.

Date :
  1. Date Completed 2022-12-29
  2. Date Revised 2023-05-26
Further Info :

Pubmed ID

36083121

DOI: Digital Object Identifier

PMC9792394

Related Literature

Article Analysis
・Effects of belumosudil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.